The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...

Julie Kim has been running Takeda’s US operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval.

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ...

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...

Takeda Pharmaceutical Company ( (TAK) ) has shared an update. Takeda Pharmaceutical Company has submitted an extraordinary report detailing its decision to dissolve its specified subsidiary ...

Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...

Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...

Takeda Pharmaceutical named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but growing ranks of women leading Japanese companies.